DAB2IP and prostate carcinoma: miR-149-3p was aberrantly expressed in several cancers, including bladder cancer, prostate cancer, breast cancer, lung cancer and endometrial cancer, where miR-149-3p inhibited the activation of DAB2IP (Disabled-2 Interacting Protein) to enhance the cells viability and aggressiveness [21].